Focused On-demand Library for RNA/RNP complex-1-interacting phosphatase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O75319

UPID:

DUS11_HUMAN

Alternative names:

Dual specificity protein phosphatase 11; Phosphatase that interacts with RNA/RNP complex 1

Alternative UPACC:

O75319; B2RCT8; C9JYA6; Q6AI47; Q9BWE3

Background:

The RNA/RNP complex-1-interacting phosphatase, also known as Dual specificity protein phosphatase 11, showcases a unique enzymatic profile with RNA 5'-triphosphatase and diphosphatase activities. Despite its modest protein-tyrosine phosphatase activity, it effectively processes ATP, ADP, and O-methylfluorescein phosphate in vitro. Its ability to bind RNA suggests a pivotal role in nuclear mRNA metabolism, positioning it as a key player in cellular signaling and gene expression regulation.

Therapeutic significance:

Understanding the role of RNA/RNP complex-1-interacting phosphatase could open doors to potential therapeutic strategies. Its involvement in crucial cellular processes underscores its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.